Targeting KRAS in Colorectal Cancer

Area of Science:

• Oncology
• Molecular Biology
• Genomics

Background:

• KRAS mutations are frequent genomic alterations in human cancers.
• Despite decades of effort, no KRAS-targeting therapy has been approved.
• Recent progress involves targeting the KRAS G12C mutation with specific covalent inhibitors.

Purpose of the Study:

• To review recent breakthroughs in targeting KRAS mutations, particularly KRAS G12C.
• To highlight the development and efficacy of KRAS G12C specific inhibitors.

Main Methods:

• Review of preclinical models and early-phase clinical trials.
• Analysis of data from inhibitors like sotorasib and MRTX849.
• Examination of KRAS G12C mutation prevalence in various cancers.

Main Results:

• KRAS G12C mutations are found in 14% of NSCLC and 3% of colorectal cancer.
• Potent KRAS G12C inhibitors show significant activity in preclinical models.
• Early clinical trials indicate promising antitumor activity in NSCLC, colorectal cancer, and other solid tumors with KRAS G12C mutations.

Conclusions:

• Preclinical success in targeting KRAS has translated into clinical benefits.
• KRAS G12C inhibitors hold potential to transform the management of KRAS-mutated solid tumors.
• Further research is needed for biomarkers predicting response and overcoming resistance.